Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Sr. Director-Investor Relations & Treasury Josh Gitelson, Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Fourth Quarter and Fiscal 2024 Results; Provides Fiscal 2025 Guidance Boston, MA, May 9, 2024 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quart ...

Financial release accessible online BOSTON, May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024. The conference call and webcast can be accessed with the following information: Telecon ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and Haemonetics (HAE) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis ...

In its upcoming report, Haemonetics (HAE) is predicted by Wall Street analysts to post quarterly earnings of $0.88 per share, reflecting an increase of 14.3% compared to the same period last year. Revenues are forecasted to be $326.95 million, representing a year-over-year increase of 7.4%. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ov ...

Haemonetics’ (HAE) major growth drivers include Plasma and the Hospital business. However, rising costs are a concern. The stock carries a Zacks Rank #3 (Hold) currently. Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. The demand for source plasma has been growing due to an expanding end-user market for plasma-derived biopharmaceuticals. The business also offers software solutions to support the o ...

Haemonetics (HAE) is likely to grow in the coming quarters due to its evolving Hospital portfolio, which is creating new opportunities for growth and diversification. The favorable prospects within the Plasma franchise also buoy optimism. The robust utilization of TEG disposables in the United States and China is driving revenues in Hemostasis Management, which is highly encouraging. Meanwhile, the impacts of economic uncertainties and foreign exchange remain concerns for the company’s operations. In the pa ...

BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024. The call can be accessed via teleconference at: Q4 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will rec ...

Haemonetics Corporation (HAE) announced receipt of the FDA 510(k) clearance for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge expands Haemonetics' TEG 6s viscoelastic testing capabilities to include fully heparinized patients undergoing adult cardiovascular surgeries/procedures and liver transplants in both laboratory and point-of-care settings. The recent development will fortify Haemonetics’ portfolio of hemostasis diagnostic systems. More on TEG 6s Cartrid ...

BOSTON, April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardio ...

财务数据和关键指标变化 - 第三季度收入为3.36亿美元,同比增长10%,调整后每股收益为1.04美元,同比增长22% [2][3] - 第三季度调整后毛利率为55.3%,同比增加280个基点,年度累计调整后毛利率为54.5%,同比增加80个基点 [6] - 第三季度调整后营业利润为7340万美元,同比增加1400万美元,调整后营业利润率为21.8%,同比增加250个基点 [6] - 公司预计2024财年调整后每股收益将在3.90美元至4.00美元之间,同比增长约30% [8] - 公司预计2024财年自由现金流(不含重组相关成本)将在1.6亿美元至1.8亿美元之间 [8] 各条业务线数据和关键指标变化 血浆业务 - 第三季度血浆收入同比增长10%-12%,公司提高全年指引至11%-13% [3][4] - 公司推出的Persona技术已完成2500万次采集,平均提升采集量9%-12% [3] - 新推出的Express Plus技术已完成5万次采集,显著缩短采集时间,计划于2025财年初全面推出 [3] 血液中心业务 - 第三季度血液中心收入同比下降3%,年度累计下降1% [4] - 血浆采集收入同比下降1%,但年度累计增长2% [4] - 全血收入同比下降6%,年度累计下降9%,主要受到公司精简部分业务的影响 [4] - 公司提高全年收入指引至-2%至持平 [4] 医院业务 - 第三季度医院业务收入同比增长22%,年度累计增长17% [3][4] - 血管闭合产品收入第三季度同比增长28%,年度累计增长29% [4] - 血液管理技术收入第三季度同比增长18%,年度累计增长14% [4] - 公司维持医院业务全年收入增长16%-18%的指引 [4] 各个市场数据和关键指标变化 - 国际市场Vascular Closure产品在第三季度贡献了约200个基点的收入增长 [24] - 公司计划复制在美国市场的成功经验,在欧洲等市场采取直销和分销商相结合的方式拓展Vascular Closure业务 [25] - 日本市场Vascular Closure产品获得了有利的报销政策,有助于产品的推广 [25] 公司战略和发展方向及行业竞争 - 公司致力于通过产品组合的演化、卓越的运营和资源配置,巩固在血浆市场的领导地位,同时快速发展高增长高毛利的医院业务 [3] - 公司计划在未来4年内将医院业务收入再翻一番,使其成为公司最大的业务板块 [9] - 公司将继续通过并购等方式优化资本配置,实现价值创造,并在未来2年内将总收入能力扩大至20亿美元 [9] - 公司正在与CSL等客户进行平稳有序的过渡,同时也在积极拓展其他客户以保持血浆业务的持续增长 [18][19] 管理层对经营环境和未来前景的评论 - 管理层对血浆市场的供需情况保持乐观,认为无论经济环境如何,公司都能保持较高的采集量 [18] - 管理层对医院业务的发展前景充满信心,认为通过产品创新和并购等方式,该业务有望在未来4年内实现翻番 [9] - 管理层表示,公司正在通过提高生产效率、优化产品组合等措施来应对当前的通胀压力,并有信心在2024财年实现至少200个基点的营业利润率扩张 [7][9] 问答环节重要的提问和回答 问题1 **Anthony Petrone提问** 询问公司对CSL业务过渡的具体情况 [18][19] **Chris Simon回答** 公司正在与CSL进行平稳有序的过渡,同时也在积极拓展其他客户以保持血浆业务的持续增长 [18][19] 问题2 **Larry Solow提问** 询问公司是否会通过Persona和Express Plus技术获得更多定价空间 [19][20] **Chris Simon回答** 公司将根据技术带来的价值为客户提供适当的溢价,但不会透露具体的定价策略 [19][20] 问题3 **Andrew Cooper提问** 询问公司在国际市场拓展Vascular Closure业务的计划 [24][25] **Chris Simon回答** 公司计划复制在美国市场的成功经验,在欧洲等市场采取直销和分销商相结合的方式拓展Vascular Closure业务,并利用有利的报销政策推动日本市场的发展 [24][25]